Stem cell transplantation in Hodgkin lymphoma
- PMID: 25459181
- DOI: 10.1016/j.hoc.2014.08.011
Stem cell transplantation in Hodgkin lymphoma
Abstract
Patients with Hodgkin lymphoma (HL) who relapse following effective front-line therapy are offered salvage second-line chemotherapy regimens followed by high-dose therapy and autologous stem cell transplantation (HDT/ASCT). Randomized studies comparing HDT/ASCT with conventional chemotherapy in patients with relapsed refractory HL have shown significant improvement in progression-free survival and freedom from treatment failure but were not powered to show improvements in overall survival. For patients who relapse after salvage HDT/ASCT, novel therapies exist as a bridge to allogeneic SCT. In this article, we review indications and results of autologous and allogeneic SCT in HL.
Keywords: Brentuximab-vedotin; Donor-lymphocyte infusion; Hodgkin lymphoma; Stem cell transplantation.
Copyright © 2014 Elsevier Inc. All rights reserved.
Similar articles
-
A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.Turk J Pediatr. 2019;61(5):671-676. doi: 10.24953/turkjped.2019.05.005. Turk J Pediatr. 2019. PMID: 32104998
-
Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience.Intern Med J. 2017 May;47(5):574-578. doi: 10.1111/imj.13415. Intern Med J. 2017. PMID: 28247950
-
The role of autologous stem-cell transplantation in classical Hodgkin lymphoma in the modern era.Semin Hematol. 2024 Aug;61(4):253-262. doi: 10.1053/j.seminhematol.2024.06.003. Epub 2024 Jun 28. Semin Hematol. 2024. PMID: 39039012 Review.
-
Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.Expert Opin Biol Ther. 2016;16(3):347-64. doi: 10.1517/14712598.2015.1130821. Epub 2016 Feb 6. Expert Opin Biol Ther. 2016. PMID: 26652934
-
Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma.Ann Hematol. 2016 Sep;95(9):1521-35. doi: 10.1007/s00277-016-2736-5. Epub 2016 Jul 4. Ann Hematol. 2016. PMID: 27376363
Cited by
-
Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin's Lymphoma: Recent Advances and Outcomes.J Pers Med. 2022 Jan 18;12(2):125. doi: 10.3390/jpm12020125. J Pers Med. 2022. PMID: 35207613 Free PMC article. Review.
-
Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen.Br J Haematol. 2016 Jan;172(1):111-21. doi: 10.1111/bjh.13803. Epub 2015 Oct 12. Br J Haematol. 2016. PMID: 26458240 Free PMC article.
-
CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma.Haematologica. 2018 Apr;103(4):655-665. doi: 10.3324/haematol.2017.178384. Epub 2018 Jan 19. Haematologica. 2018. PMID: 29351987 Free PMC article.
-
Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies.Biol Blood Marrow Transplant. 2016 Jan;22(1):17-22. doi: 10.1016/j.bbmt.2015.10.014. Epub 2015 Oct 17. Biol Blood Marrow Transplant. 2016. PMID: 26485445 Free PMC article. Review.
-
Safety and efficacy of anti-CD30 CAR-T cell therapy in relapsed/refractory classic Hodgkin lymphoma: a systematic review and meta-analysis.BMC Cancer. 2025 Jan 14;25(1):78. doi: 10.1186/s12885-024-13400-5. BMC Cancer. 2025. PMID: 39806291 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
